View Older Stories View More Recent Stories

Oct 21, 2024 07:30AM Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough
Oct 15, 2024 07:30AM Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences
Oct 3, 2024 04:11PM Trevi Therapeutics (TRVI) Provides Update on Haduvio's Clinical Development Program
Oct 3, 2024 04:05PM Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program
Sep 30, 2024 05:42PM Trevi Therapeutics (TRVI) Appoints James V. Cassella as Chief Development Officer
Sep 30, 2024 05:30PM Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer
Sep 26, 2024 07:30AM Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024
Sep 4, 2024 04:05PM Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024
Aug 28, 2024 07:30AM Trevi Therapeutics to Participate in September Investor and Medical Conferences
Aug 8, 2024 04:05PM Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance
Aug 1, 2024 07:30AM Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024
Jul 2, 2024 07:30AM Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events
May 9, 2024 07:30AM Trevi Therapeutics to Participate in Upcoming Conferences
May 7, 2024 04:05PM Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 1, 2024 04:05PM Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024
Apr 9, 2024 07:30AM Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
Apr 4, 2024 07:30AM Trevi Therapeutics to Participate in Upcoming April Events
Apr 2, 2024 07:32AM Trevi Therapeutics (TRVI) Adds Clinical Development Expertise in Chronic Cough to Leadership Team
Apr 2, 2024 07:30AM Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
Mar 20, 2024 04:05PM Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
Mar 13, 2024 04:05PM Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024
Feb 28, 2024 07:30AM Trevi Therapeutics to Participate in Upcoming March Events
Feb 6, 2024 07:30AM Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Jan 4, 2024 07:33AM Trevi Therapeutics (TRVI) Provides Business Updates
Jan 4, 2024 07:30AM Trevi Therapeutics Provides Business Updates
Dec 5, 2023 07:30AM Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)
Nov 9, 2023 04:05PM Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update
Nov 2, 2023 07:30AM Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio™ for Refractory Chronic Cough
Nov 1, 2023 04:05PM Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023
Oct 13, 2023 08:30AM Trevi Therapeutics (TRVI) Reports Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio
Oct 13, 2023 08:30AM Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio™ in Prurigo Nodularis
Sep 6, 2023 07:30AM Trevi Therapeutics to Participate in Upcoming September Events
Aug 10, 2023 04:05PM Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update
Aug 3, 2023 04:05PM Trevi Therapeutics to Report Q2 2023 Financial Results and Provide a Corporate Update on August 10, 2023
Aug 1, 2023 07:30AM Trevi Therapeutics to Participate in Upcoming August Events
Jul 6, 2023 07:30AM Trevi Therapeutics to Participate in Upcoming July Investor Events
May 30, 2023 07:30AM Trevi Therapeutics to Participate in Upcoming June Conferences
May 22, 2023 04:05PM Trevi Therapeutics (TRVI) Announces Publication of Positive Data from the CANAL Trial
May 22, 2023 04:05PM Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial in IPF Chronic Cough in NEJM Evidence
May 11, 2023 04:05PM Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update
May 9, 2023 07:30AM Trevi Therapeutics to Present at Upcoming Yale Innovation Summit 2023
May 4, 2023 04:05PM Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023
May 2, 2023 07:30AM Trevi Therapeutics Announces Two Presentations on the Phase 2 CANAL Data at the ATS 2023 International Conference
Apr 27, 2023 07:30AM Trevi Therapeutics to Participate in Upcoming May Investor Events
Apr 11, 2023 04:05PM Trevi Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference
Mar 16, 2023 04:05PM Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update
Mar 9, 2023 04:05PM Trevi Therapeutics to Report Q4 and Year End 2022 Financial Results and Provide a Corporate Update on March 16, 2023
Mar 8, 2023 07:32AM Trevi Therapeutics (TRVI) Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis
Mar 8, 2023 07:30AM Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis
Mar 6, 2023 04:05PM Trevi Therapeutics to Participate in Upcoming March Conferences
View More Recent Stories View Older Stories